Is chymase 1 a therapeutic target in cardiovascular disease?-Reference-Cited by-同舟云学术

Is chymase 1 a therapeutic target in cardiovascular disease?

Published:2023-08-03 Issue:8 Volume:27 Page:645-656
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Ferrario Carlos M¹,Ahmad Sarfaraz¹,Speth Robert²,Dell’Italia Louis J³⁴

Affiliation:

1. Laboratory of Translational Hypertension and Vascular Research, Department of Surgery, Wake Forest School of Medicine, Winston Salem, NC, USA

2. Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, Florida, USA

3. Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham (UAB), Birmingham, AL, USA

4. Birmingham Department of Veterans Affairs Health Care System, Birmingham, AL, USA

Funder

National Institutes of Health

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2023.2247561

Reference145 articles.

1. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

2. Khalil H, Zeltser R. Antihypertensive Medications. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

3. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension

4. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis

5. Aitken M, Kleinrock M, Pritchett J. The use of medicines in the U.S.: usage and spending trends and outlook to 2026. IQVIA Institute for Human Data Science; 2022. p. 64. https://www.iqvia.com/insights/the-iqvia-institute/reports/the-use-of-medicines-in-the-us